• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚(ADP - 核糖)聚合酶抑制剂与DNA损伤剂在卵巢肿瘤细胞系中的联合效应——特别提及顺铂

Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.

作者信息

Bernges F, Zeller W J

机构信息

German Cancer Research Center, Heidelberg, Germany.

出版信息

J Cancer Res Clin Oncol. 1996;122(11):665-70. doi: 10.1007/BF01209029.

DOI:10.1007/BF01209029
PMID:8898976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12200429/
Abstract

The effects of the poly(ADP-ribose) polymerase inhibitors 4-amino-1,8-naphthalimide (4-ANI), 6(5H)-phenanthridinone (PHD), 1,5-isoquinolinediol (IQD), 3-aminobenzamide (3-AB) or 4-hydroxyquinazoline (4-HYA) on the cytotoxicity of cisplatin were investigated. The human ovarian tumor cell lines SK-OV-3 and OAW 42 and the rat ovarian tumor cell line O-342 as well as its cisplatin (DDP)-resistant subline O-342/DDP were used. Cytotoxicity was determined with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG) plus its respective combinations with poly(ADP-ribose) polymerase inhibitors served as positive controls. In addition, the alkylating agents L-threitol-1,4-bismethanesulfonate (DHB) and 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine) as well as two other DNA-repair inhibitors caffeine and theophylline were included in the investigations. The cytotoxicity of cisplatin could not be increased by 4-ANI, PHD, IQD, 4-HYA or 3-AB in any cell line investigated, while it was increased by caffeine in lines O-342/DDP and SK-OV-3 as well as by theophylline in lines O-342/DDP, SK-OV-3 and OAW 42. The cytotoxicity of MNNG was increased by combination with 4-ANI, PHD, IQD, 4-HYA, 3-AB or theophylline for all lines except OAW42; in the latter line, only 4-ANI, PHD and IQD increased MNNG cytotoxicity. The cytotoxicity of DHB was increased by 4-ANI, PHD, 4-HYA, theophylline and caffeine in line O-342/DDP; by 4-HYA, theophylline and caffeine in line SK-OV-3; and by theophylline and caffeine in line OAW42. The cytotoxicity of carmustine was increased only by 3-AB in two lines (SK-OV-3 and OAW 42). Results are discussed with regard to different DNA-repair mechanisms.

摘要

研究了聚(ADP - 核糖)聚合酶抑制剂4 - 氨基 - 1,8 - 萘二甲酰亚胺(4 - ANI)、6(5H) - 菲啶酮(PHD)、1,5 - 异喹啉二醇(IQD)、3 - 氨基苯甲酰胺(3 - AB)或4 - 羟基喹唑啉(4 - HYA)对顺铂细胞毒性的影响。使用了人卵巢肿瘤细胞系SK - OV - 3和OAW 42、大鼠卵巢肿瘤细胞系O - 342及其顺铂(DDP)耐药亚系O - 342/DDP。用3 - (4,5 - 二甲基噻唑 - 2 - 基) - 2,5 - 二苯基四氮唑溴盐(MTT)法测定细胞毒性。1 - 甲基 - 3 - 硝基 - 1 - 亚硝基胍(MNNG)及其与聚(ADP - 核糖)聚合酶抑制剂的各自组合作为阳性对照。此外,研究中还包括烷基化剂L - 苏糖醇 - 1,4 - 双甲磺酸酯(DHB)和1,3 - 双(2 - 氯乙基) - 1 - 亚硝基脲(卡莫司汀)以及另外两种DNA修复抑制剂咖啡因和茶碱。在所研究的任何细胞系中,4 - ANI、PHD、IQD、4 - HYA或3 - AB均不能增加顺铂的细胞毒性,而咖啡因在O - 342/DDP和SK - OV - 3细胞系中可增加其细胞毒性,茶碱在O - 342/DDP、SK - OV - 3和OAW 42细胞系中可增加其细胞毒性。除OAW42细胞系外,MNNG与4 - ANI、PHD、IQD、4 - HYA、3 - AB或茶碱联合使用可增加其细胞毒性;在后者细胞系中,只有4 - ANI、PHD和IQD可增加MNNG的细胞毒性。在O - 342/DDP细胞系中,4 - ANI、PHD、4 - HYA、茶碱和咖啡因可增加DHB的细胞毒性;在SK - OV - 3细胞系中,4 - HYA、茶碱和咖啡因可增加其细胞毒性;在OAW42细胞系中,茶碱和咖啡因可增加其细胞毒性。卡莫司汀的细胞毒性仅在SK - OV - 3和OAW 42两个细胞系中被3 - AB增加。针对不同的DNA修复机制对结果进行了讨论。

相似文献

1
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.聚(ADP - 核糖)聚合酶抑制剂与DNA损伤剂在卵巢肿瘤细胞系中的联合效应——特别提及顺铂
J Cancer Res Clin Oncol. 1996;122(11):665-70. doi: 10.1007/BF01209029.
2
In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.大鼠卵巢肿瘤细胞系中顺铂耐药性诱导及逆转的体外研究
J Cancer Res Clin Oncol. 1990;116(5):443-7. doi: 10.1007/BF01612991.
3
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚(ADP-核糖)聚合酶(PARP)抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.用于治疗卵巢癌的聚(ADP - 核糖)聚合酶(PARP)抑制剂。
Cochrane Database Syst Rev. 2015 May 20;2015(5):CD007929. doi: 10.1002/14651858.CD007929.pub3.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
8
DNA-repair pathway inhibitors for the treatment of ovarian cancer.用于治疗卵巢癌的DNA修复途径抑制剂
Cochrane Database Syst Rev. 2010 Jun 16(6):CD007929. doi: 10.1002/14651858.CD007929.pub2.
9
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.PARP1和PARP14的新型抑制剂:设计、合成及增强顺铂在癌症治疗中的疗效
Future Med Chem. 2025 Jan;17(1):35-58. doi: 10.1080/17568919.2024.2437972. Epub 2024 Dec 18.
10
Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.卵巢癌中通过降低半胱天冬酶-3活性和抗凋亡蛋白过表达来抵抗化疗诱导的细胞凋亡。
J Cancer Res Clin Oncol. 2004 Jul;130(7):423-8. doi: 10.1007/s00432-004-0556-9.

引用本文的文献

1
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions.聚(ADP-核糖)聚合酶(PARP)抑制剂在癌症治疗中的应用:进展、挑战与未来方向。
Biomolecules. 2024 Oct 9;14(10):1269. doi: 10.3390/biom14101269.
2
SMC5/6 complex-mediated SUMOylation stimulates DNA-protein cross-link repair in Arabidopsis.SMC5/6 复合物介导的 SUMOylation 刺激拟南芥中的 DNA-蛋白质交联修复。
Plant Cell. 2023 Apr 20;35(5):1532-1547. doi: 10.1093/plcell/koad020.
3
Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity.紫朱草素诱导的氧化性DNA损伤与PARP抑制协同作用引发癌症特异性细胞毒性。
Front Pharmacol. 2020 Dec 22;11:610205. doi: 10.3389/fphar.2020.610205. eCollection 2020.
4
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.联合 PARP 抑制剂与铂、钌或金配合物用于癌症治疗。
ChemMedChem. 2020 Nov 18;15(22):2121-2135. doi: 10.1002/cmdc.202000391. Epub 2020 Sep 10.
5
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.双联枪:PARP 抑制剂与常规化疗联合。
Pharmacol Ther. 2018 Aug;188:168-175. doi: 10.1016/j.pharmthera.2018.03.006. Epub 2018 Apr 3.
6
Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.聚(二磷酸腺苷-核糖)聚合酶作为治疗靶点:从其抑制剂中吸取的经验教训。
Oncotarget. 2017 Jul 25;8(30):50221-50239. doi: 10.18632/oncotarget.16859.
7
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.曲贝替定和聚(ADP-核糖)聚合酶抑制剂鲁卡帕尼在软组织肉瘤中的活性。
J Hematol Oncol. 2017 Apr 11;10(1):84. doi: 10.1186/s13045-017-0451-x.
8
An update on PARP inhibitors for the treatment of cancer.PARP抑制剂治疗癌症的最新进展。
Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
9
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.PARP 抑制剂的治疗应用:抗癌治疗及其他。
Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
10
The role of PARP in DNA repair and its therapeutic exploitation.PARP 在 DNA 修复中的作用及其治疗性开发。
Br J Cancer. 2011 Oct 11;105(8):1114-22. doi: 10.1038/bjc.2011.382.

本文引用的文献

1
The molecular biology of apoptosis.细胞凋亡的分子生物学
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2239-44. doi: 10.1073/pnas.93.6.2239.
2
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.DNA链断裂诱导的聚(ADP-核糖)聚合酶的翻译后修饰
Trends Biochem Sci. 1995 Oct;20(10):405-11. doi: 10.1016/s0968-0004(00)89089-1.
3
Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae.酿酒酵母无细胞提取物中DNA的核苷酸切除修复
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4907-11. doi: 10.1073/pnas.90.11.4907.
4
Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells.聚(ADP - 核糖)聚合酶DNA结合域的过度产生会阻碍哺乳动物细胞中烷基化诱导的DNA修复合成。
EMBO J. 1993 May;12(5):2109-17. doi: 10.1002/j.1460-2075.1993.tb05859.x.
5
Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.DNA修复在细胞对烷化剂和顺铂耐药机制中的作用。
Cancer Chemother Pharmacol. 1993;32(2):85-9. doi: 10.1007/BF00685607.
6
Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment.顺铂处理使完整细胞中多聚(ADP - 核糖基)化增加。
Carcinogenesis. 1993 Apr;14(4):559-61. doi: 10.1093/carcin/14.4.559.
7
Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death.咖啡因增强顺铂的细胞毒性表现为凋亡性细胞死亡。
Exp Cell Res. 1994 Feb;210(2):236-42. doi: 10.1006/excr.1994.1035.
8
Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.烟酰胺在体外和体内逆转获得性顺铂耐药性
Cancer Chemother Pharmacol. 1993;33(2):157-62. doi: 10.1007/BF00685335.
9
Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs.
Cancer Chemother Pharmacol. 1994;34(2):153-8. doi: 10.1007/BF00685933.
10
Platinum resistance. Experimental and clinical status.铂电阻。实验与临床现状。
Hematol Oncol Clin North Am. 1994 Apr;8(2):411-29.